Meridian Bioscience Stock

Meridian Bioscience ROE

The Return on Equity (ROE) of Meridian Bioscience (VIVO) as of Sep 11, 2026 is 11.54 %. In the previous year, Return on Equity (ROE) was 21.75 % — a change of -46.96% (lower).

ROE

11.54 %

YoY

-46.96%

Last updated:

In 2026, Meridian Bioscience's return on equity (ROE) was 11.54 %, a -46.96% increase from the 21.75 % ROE in the previous year.

The Meridian Bioscience ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2015
21.40 USD
Jan 1, 2016
19.34 USD
Jan 1, 2017
12.74 USD
Jan 1, 2018
13.57 USD
Jan 1, 2019
12.77 USD
Jan 1, 2020
18.66 USD
Jan 1, 2021
21.75 USD
Jan 1, 2022
11.54 USD
The Meridian Bioscience ROE history
YEARROEYoY
11.54 %-46.96%
21.75 %+16.57%
18.66 %+46.06%
12.77 %-5.85%
13.57 %+6.54%
12.74 %-34.15%
19.34 %-9.62%
21.40 %-0.72%
21.55 %—
Access this data via the Eulerpool API
Get Free API Key

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

ROE Details

Decoding Meridian Bioscience's Return on Equity (ROE)

Meridian Bioscience's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Meridian Bioscience's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Meridian Bioscience's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Meridian Bioscience’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Meridian Bioscience stock

Return on Equity (ROE) of Meridian Bioscience is 11.54 % in 2026.

Return on Equity (ROE) of Meridian Bioscience changed from 21.75 % to 11.54 %, representing a -46.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Meridian Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Meridian Bioscience

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Meridian Bioscience